Articles producció científica> Medicina i Cirurgia

Real-World Outcomes with Lomitapide Use in Paediatric Patients with Homozygous Familial Hypercholesterolaemia.

  • Dades identificatives

    Identificador: imarina:5671202
    Autors:
    Ben-Omran T, Masana L, Kolovou G, Ariceta G, Nóvoa FJ, Lund AM, Bogsrud MP, Araujo M, Hussein O, Ibarretxe D, Sanchez-Hernández RM, Santos RD
    Resum:
    Homozygous familial hypercholesterolaemia (HoFH) is a rare, autosomal disease affecting the clearance of low-density lipoprotein cholesterol (LDL-C) from circulation, and leading to early-onset atherosclerotic cardiovascular disease (ASCVD). Treatment consists mainly of statins, lipoprotein apheresis (LA) and, more recently, the microsomal triglyceride transfer protein inhibitor lomitapide. Lomitapide is not licensed for use in children, but has been made available through an expanded access programme or on a named patient basis.This case series includes 11 HoFH patients in 10 different centres in eight countries, less than 18 years of age (mean 11.6?±?1.1 years, 64% male), with signs of ASCVD, and who have received treatment with lomitapide (mean dose 24.5?±?4.3 mg/day; mean exposure 20.0?±?2.9 months). Background lipid-lowering therapy was given according to local protocols. Lomitapide was commenced with a stepwise dose escalation from 2.5 mg or 5 mg/day; dietary advice and vitamin supplements were provided as per the product label for adults. Laboratory analysis was conducted as part of regular clinical care.In the 11 cases, mean baseline LDL-C was 419?±?74.6 mg/dL and was markedly reduced by lomitapide to a nadir of 176.7?±?46.3 mg/dL (58.4?±?6.8% decrease). Six patients achieved recommended target levels for children below 135 mg/dL, five of whom had LA frequency reduced. In one case, LDL-C levels were close to target when lomitapide was started but remained stable despite 75% reduction in LA frequency (from twice weekly to biweekly). Adverse events were mainly gastrointestinal in nature, occurred early in the treatment course and were well managed. Three patients with excursions in liver function tests were managed chiefly without intervention; two patients had de
  • Altres:

    Autor segons l'article: Ben-Omran T, Masana L, Kolovou G, Ariceta G, Nóvoa FJ, Lund AM, Bogsrud MP, Araujo M, Hussein O, Ibarretxe D, Sanchez-Hernández RM, Santos RD
    Departament: Medicina i Cirurgia
    Autor/s de la URV: Masana Marín, Luis
    Paraules clau: Transfer protein inhibitor Safety Real-world data Patient cases Paediatric Low-density lipoprotein cholesterol Lomitapide Lipidology Ldl-apheresis Insights Homozygous familial hypercholesterolaemia Guidance Experience Efficacy Density-lipoprotein apheresis Clinician Cardiology Atherosclerosis Adverse events patient cases paediatric low-density lipoprotein cholesterol lomitapide lipidology homozygous familial hypercholesterolaemia cardiology atherosclerosis adverse events
    Resum: Homozygous familial hypercholesterolaemia (HoFH) is a rare, autosomal disease affecting the clearance of low-density lipoprotein cholesterol (LDL-C) from circulation, and leading to early-onset atherosclerotic cardiovascular disease (ASCVD). Treatment consists mainly of statins, lipoprotein apheresis (LA) and, more recently, the microsomal triglyceride transfer protein inhibitor lomitapide. Lomitapide is not licensed for use in children, but has been made available through an expanded access programme or on a named patient basis.This case series includes 11 HoFH patients in 10 different centres in eight countries, less than 18 years of age (mean 11.6?±?1.1 years, 64% male), with signs of ASCVD, and who have received treatment with lomitapide (mean dose 24.5?±?4.3 mg/day; mean exposure 20.0?±?2.9 months). Background lipid-lowering therapy was given according to local protocols. Lomitapide was commenced with a stepwise dose escalation from 2.5 mg or 5 mg/day; dietary advice and vitamin supplements were provided as per the product label for adults. Laboratory analysis was conducted as part of regular clinical care.In the 11 cases, mean baseline LDL-C was 419?±?74.6 mg/dL and was markedly reduced by lomitapide to a nadir of 176.7?±?46.3 mg/dL (58.4?±?6.8% decrease). Six patients achieved recommended target levels for children below 135 mg/dL, five of whom had LA frequency reduced. In one case, LDL-C levels were close to target when lomitapide was started but remained stable despite 75% reduction in LA frequency (from twice weekly to biweekly). Adverse events were mainly gastrointestinal in nature, occurred early in the treatment course and were well managed. Three patients with excursions in liver function tests were managed chiefly without intervention; two patients had decreases in lomitapide dose.Lomitapide demonstrated promising effectiveness in paediatric HoFH patients. Adverse events were manageable, and the clinical profile of the drug is apparently similar to that in adult patients.Amryt Pharma.
    Àrees temàtiques: Pharmacology (medical) Pharmacology & pharmacy Medicine, research & experimental Medicine (miscellaneous) Medicina iii Medicina ii Medicina i General medicine
    Accès a la llicència d'ús: https://creativecommons.org/licenses/by/3.0/es/
    ISSN: 0741238X
    Adreça de correu electrònic de l'autor: luis.masana@urv.cat
    Identificador de l'autor: 0000-0002-0789-4954
    Data d'alta del registre: 2023-02-18
    Versió de l'article dipositat: info:eu-repo/semantics/publishedVersion
    Enllaç font original: https://link.springer.com/article/10.1007%2Fs12325-019-00985-8
    Referència a l'article segons font original: Advances In Therapy. 36 (7): 1786-1811
    Referència de l'ítem segons les normes APA: Ben-Omran T, Masana L, Kolovou G, Ariceta G, Nóvoa FJ, Lund AM, Bogsrud MP, Araujo M, Hussein O, Ibarretxe D, Sanchez-Hernández RM, Santos RD (2019). Real-World Outcomes with Lomitapide Use in Paediatric Patients with Homozygous Familial Hypercholesterolaemia.. Advances In Therapy, 36(7), 1786-1811. DOI: 10.1007/s12325-019-00985-8
    URL Document de llicència: https://repositori.urv.cat/ca/proteccio-de-dades/
    DOI de l'article: 10.1007/s12325-019-00985-8
    Entitat: Universitat Rovira i Virgili
    Any de publicació de la revista: 2019
    Tipus de publicació: Journal Publications
  • Paraules clau:

    Medicine (Miscellaneous),Medicine, Research & Experimental,Pharmacology & Pharmacy,Pharmacology (Medical)
    Transfer protein inhibitor
    Safety
    Real-world data
    Patient cases
    Paediatric
    Low-density lipoprotein cholesterol
    Lomitapide
    Lipidology
    Ldl-apheresis
    Insights
    Homozygous familial hypercholesterolaemia
    Guidance
    Experience
    Efficacy
    Density-lipoprotein apheresis
    Clinician
    Cardiology
    Atherosclerosis
    Adverse events
    patient cases
    paediatric
    low-density lipoprotein cholesterol
    lomitapide
    lipidology
    homozygous familial hypercholesterolaemia
    cardiology
    atherosclerosis
    adverse events
    Pharmacology (medical)
    Pharmacology & pharmacy
    Medicine, research & experimental
    Medicine (miscellaneous)
    Medicina iii
    Medicina ii
    Medicina i
    General medicine
  • Documents:

  • Cerca a google

    Search to google scholar